check_circleStudy Completed

Amyloid Cardiomyopathy

Bayer Identifier:
AG10-201
ClinicalTrials.gov Identifier:
NCT03458130
EudraCT Number:
Not Available
EU CT Number:
Not Available
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients with Symptomatic Transthyretin Amyloid Cardiomyopathy

Trial purpose

Key Participants Requirements

Sex

N/A

Age

N/A

    Trial summary

    Enrollment Goal
    N/A
    Trial Dates
    April 2018 - October 2018
    Phase
    Phase 2
    Could I Receive a placebo
    N/A
    Products
    Acoramidis (BAY3684938)
    Accepts Healthy Volunteer
    N/A

    Trial design

    A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients with Symptomatic Transthyretin Amyloid Cardiomyopathy
    Trial Type
    Interventional
    Intervention Type
    N/A
    Trial Purpose
    N/A
    Allocation
    N/A
    Blinding
    N/A
    Assignment
    N/A
    Trial Arms
    N/A